Stephen Kanes - 03 Feb 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Medical Officer
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
03 Feb 2025
Net transactions value
$0
Form type
4
Filing time
04 Feb 2025, 16:57:29 UTC
Previous filing
16 Jan 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +500,000 $0.000000 500,000 03 Feb 2025 Ordinary Shares 500,000 $16.90 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option shall vest and become exercisable on February 3, 2026 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments thereafter.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.